Here's a summary of Viyash Scientific's investor presentation, tailored for retail investors: **1. Business Performance:** Viyash Scientific delivered a strong FY26, with Q4 being its best quarter ever.

Revenues grew 13.8% YoY to ₹34,203 Cr for the full year, driven by robust performance in Formulations (+18% YoY) and APIs (+8% YoY). Key growth geographies include Europe (+19% YoY) and Emerging Markets (+23% YoY). **2. Growth Drivers or Strategy:** The company is focused on realizing synergies from its recent integration, which has improved operational efficiency and resilience.

They are actively evaluating inorganic opportunities to further strengthen their platform. **3. Recent Developments:** The merger process is complete and in effect.

Viyash is now focused on synergy realization, which is well on track. **4. Key Financial Metrics:** For FY26, Revenue stood at ₹34,203 Cr, a 13.8% YoY increase.

EBITDA grew by 59.6% YoY to ₹7,025 Cr.

Net Debt to LTM EBITDA improved significantly to 0.2x from 1.0x in FY25. **5. Management Commentary / Outlook:** Management is excited about the product pipeline and growth roadmap for FY27. With a deleveraged balance sheet, they are strategically positioned to pursue growth and create long-term value.